NCM · Industrial - Distribution

BioNexus Gene Lab Corp (BGLC) Stock

$1.29 +3.20% NCM: BGLC Industrials

Valuation

MetricValue
Price$1.29
Market Cap$3.12M
P/E Ratio-1.01
P/B Ratio0.39
P/S Ratio0.98
EPS (TTM)$0.00
52-Week High$5.89
52-Week Low$1.07
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-32.91%
ROA-29.51%
ROCE-32.71%
Gross Margin-57.14%
Operating Margin-42.86%
Net Margin-82.36%
Debt/Equity0.03
Current Ratio5.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$13.0M$11.0M$10.0M$10.0M$7.0M
Operating Profit$1.0M$0$-3.0M$-2.0M$-3.0M
Net Profit$1.0M$0$-3.0M$-2.0M$-3.0M
EPS$0.53$-0.25$-1.53$-0.90$-1.61
Op Margin7.9%-2.7%-26.5%-16.6%-42.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$10.0M$9.0M$11.0M$10.0M$9.0M
Total Liabilities$2.0M$2.0M$2.0M$2.0M$1.0M
Cash$2.0M$2.0M$6.0M$4.0M$2.0M
Borrowings$0$0$0$0$0

Latest News

BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development GlobeNewswire · May 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$1.0M$-2.0M$-2.0M$-2.0M
Investing Cash Flow$0$-1.0M$-2.0M$0$1.0M
Financing Cash Flow$0$0$1.0M$0$0
Net Cash Flow$-1.0M$0$4.0M$-2.0M$0
Free Cash Flow$0$0$-2.0M$-2.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.09
EV / EBITDA-0.83
FCF Yield-28.35%
Quick Ratio5.28
Interest Coverage-407.16
Return 1Y-55.20%
Return 3Y-98.70%
Return 5Y-99.20%

Ownership

Insiders Held35.59%
Institutions Held0.01%
Institutions Float Held0.01%
Institutional HolderSharesReport Date
UBS Group AG2312026-03-31
Wells Fargo & Company12026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADVBAdvanced Biomed Inc. $5.31 -13.24% -29.77 $7.34M 0.00%
AEONAEON Biopharma, Inc. $0.28 -10.97% -0.08 $12.19M 0.00%
APM $0.81 -0.78% -4.42 $5.15M 0.00%
CHEKCheck-Cap Ltd. $1.86 +1.64% -0.43 $10.88M 0.00%
GLTODamora Therapeutics, Inc. $21.58 -3.36% -0.17 $34.47M 0.00%

About BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is led by CEO Su-Leng Tan, employs 30 people, headquartered in MY, publicly traded since 2021.

BioNexus Gene Lab Corp (BGLC) stock trades at $1.29 with a market capitalization of $3.12M. The stock is valued at a price-to-earnings (P/E) ratio of -1.01, price-to-book of 0.39, price-to-sales of 0.98. Over the past 52 weeks the stock has ranged between $1.07 and $5.89, and currently trades 78.1% below its 52-week high.

On profitability, BioNexus Gene Lab Corp generates a return on equity (ROE) of -32.91%, return on capital employed of -32.71%, an operating margin of -42.86%, a net profit margin of -82.36%.

Related Industrials Stocks

SPCX Space Exploration Technologies Corp. $162.57 +1.25% CAT Caterpillar, Inc. $800.47 +0.54% GE GE Aerospace $308.20 +0.84% RTX RTX Corporation $185.97 +0.90% DE Deere & Company $620.93 -4.85% ETN Eaton Corporation, PLC $429.65 +1.21% UNP Union Pacific Corporation $278.34 +0.05% BA Boeing Company (The) $190.37 +1.40% PH Parker-Hannifin Corporation $962.56 +1.65% LMT Lockheed Martin Corporation $509.59 +0.33% ADP Automatic Data Processing, Inc. $271.95 +0.45% PWR Quanta Services, Inc. $705.94 +3.01%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Screens featuring this stock

High ROE Industrials StocksLow P/E Industrials StocksHigh Net Margin Industrials StocksDividend Industrials StocksLow Debt Industrials StocksAll stock screens
Run Stock Screener Investing Guides